Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, combining monoclonal antibodies with potent cytotoxic drugs to deliver targeted therapies. This innovative approach maximizes the therapeutic impact while minimizing systemic toxicity, making ADCs a critical development in oncology.